Hisun Pharmaceutical Sustainability Profile
Hisun Pharmaceutical, officially known as Zhejiang Hisun Pharmaceutical Co., Ltd., is a prominent player in the global pharmaceutical industry, headquartered in CN. Founded in 1956, the company has established a strong presence in major operational regions, including Asia, Europe, and North America. Hisun Pharmaceutical focuses on the research, development, and manufacturing of a diverse range of products, including generic drugs, active pharmaceutical ingredients (APIs), and innovative therapies. With a commitment to quality and innovation, Hisun has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. The company is recognised for its unique approach to drug development, particularly in oncology and cardiovascular treatments. Hisun Pharmaceutical continues to make strides in the industry, solidifying its reputation as a trusted provider of high-quality pharmaceutical solutions.
DitchCarbon Score
How does Hisun Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hisun Pharmaceutical's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hisun Pharmaceutical's reported carbon emissions
Hisun Pharmaceutical, headquartered in China (CN), currently does not report any specific carbon emissions data, as indicated by the absence of available figures. Consequently, there are no documented Scope 1, 2, or 3 emissions to analyse. Furthermore, the company has not established any reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate action. While Hisun Pharmaceutical has not yet disclosed specific initiatives or targets, the industry trend suggests a growing emphasis on reducing carbon footprints and enhancing environmental responsibility. As the company moves forward, it may consider adopting measurable climate commitments to align with global sustainability goals and industry standards.
How Carbon Intensive is Hisun Pharmaceutical's Industry?
How Carbon Intensive is Hisun Pharmaceutical's Location?
Hisun Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hisun Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
